Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.

By T. Smilde, S. V. van Wissen, H. Awollersheim, M. Trip, J. Kastelein, A. Stalenhoef. The Lancet, 2001

1,003 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. (2004, neutral): “Interestingly, 2 other studies using an ultrasound method for imaging the vessel wall (measurement of carotid intimal medial thickness) also showed reduced progression with intensive treatment using 80 mg of atorvastatin.(19,20) Because different doses of the 2 statins were used, the potential impac”
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. (2011, background): “, undiagnosed diabetes, hypothyroidism, nephrotic syndrome).(48) Patient history should emphasize any prior diagnosis of CHD (with age at onset), current cardiovascular symptoms, use of lipid-altering agents, and presence of other CHD risk factors with particular attention to the family history of c”
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study (2008, background): “We therefore lack estimates of the true efficacy of statin treatment in such patients. The results of the atorvastatin versus simvastatin on atherosclerotic progression (ASAP) study have suggested that we should treat such patients preferably with potent statins to maximally decrease low density lip”